Online inquiry

IVTScrip™ mRNA-Anti-IL2RB, NKTR-214(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12453MR)

This product GTTS-WQ12453MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets IL2RB gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000878.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3560
UniProt ID P14784
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL2RB, NKTR-214(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ12453MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1929MR IVTScrip™ mRNA-Anti-VEGFA, AGN 150998(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AGN 150998
GTTS-WQ14988MR IVTScrip™ mRNA-Anti-CD19, SJ25C1 scFv-28Z CAR(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA SJ25C1 scFv-28Z CAR
GTTS-WQ5215MR IVTScrip™ mRNA-Anti-CD22, CAT-8015(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CAT-8015
GTTS-WQ13793MR IVTScrip™ mRNA-Anti-S, REGN-10933(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-10933
GTTS-WQ13363MR IVTScrip™ mRNA-Anti-LRRC15, PR-1498487(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PR-1498487
GTTS-WQ11910MR IVTScrip™ mRNA-Anti-CCR2, MLN-1202(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MLN-1202
GTTS-WQ13067MR IVTScrip™ mRNA-Anti-MADCAM1, PF-00547659(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PF-00547659
GTTS-WQ15423MR IVTScrip™ mRNA-Anti-LAG3, TSR-033(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA TSR-033
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW